As the sponsor of the Keynote Oncology Clinical Trials, Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer.
Pembrolizumab has been FDA-approved for use in certain types of cancer.
To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Efficacy and Safety Study of First-line Treatment With Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer||826||Cervical Cancer||Phase 3||Recruiting|
|Efficacy and Safety Study of Pembrolizumab in Women With Advanced Recurrent Ovarian Cancer||100||Ovarian Neoplasms||Phase 2||Active, not recruiting|